Zeleciment Basivarsen for Myotonic Dystrophy

This trial tests a new treatment called zeleciment basivarsen (DYNE-101) to determine its safety and effectiveness for people with myotonic dystrophy type 1 (DM1), a genetic disorder affecting muscle function. Participants will receive either the treatment or a placebo (a substance with no therapeutic effect) every 8 weeks for up to 48 weeks. Individuals who can walk 10 meters and complete a simple strength test independently, and who have DM1 confirmed by genetic testing, may be suitable for this trial. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants the opportunity to contribute to potentially bringing a new treatment to market.

The trial requires that you stop taking certain medications like GLP-1 agonists (a type of diabetes medication) before joining. If you're on these, you'll need to stop them for a specific time before the trial starts.

Research has shown that zeleciment basivarsen (DYNE-101) is generally well-tolerated in studies for myotonic dystrophy type 1 (DM1). As of April 2025, Dyne Therapeutics reports a good safety record for the treatment, with no major safety issues. Participants have experienced some improvement in muscle strength and function, indicating effectiveness without significant harm.

Unlike the standard treatments for myotonic dystrophy, which mainly focus on managing symptoms with medications like mexiletine or physical therapies, DYNE-101 offers a unique approach. DYNE-101 is designed to target the genetic root of the disease by using an advanced delivery method to silence the toxic RNA responsible for myotonic dystrophy. Researchers are excited because this approach has the potential to not just alleviate symptoms but also modify the disease's progression, offering hope for longer-term benefits.

Research has shown that the drug zeleciment basivarsen (DYNE-101) could be promising for treating myotonic dystrophy type 1 (DM1). Studies have found significant improvements in patients' strength, daily activities, and cognitive skills. These benefits arise from the treatment's ability to address the root cause of DM1. Participants in earlier trials reported enhanced movement and mental abilities. The treatment is also considered safe, offering hope for those with DM1. In this trial, participants will be randomized to receive either DYNE-101 or a placebo during the placebo-controlled period, followed by a long-term extension period where all participants will receive DYNE-101.¹²³⁴⁶